Whole Foods/Wild Oats
This article was originally published in The Tan Sheet
Executive Summary
U.S. District Court for the District of Columbia Judge Paul Friedman denies FTC's lawsuit requesting a preliminary injunction against the proposed $670 mil. merger of Whole Foods Market and Wild Oats Markets. The federal agency may appeal the Aug. 16 ruling and may seek a stay from either the District Court or the U.S. Court of Appeals for the D.C. Circuit to preclude the closing of the merger. Absent a stay pending an appeal, the firms may close the transaction any time after noon on Aug. 20. Under terms of the deal, Whole Foods will acquire all outstanding shares of Wild Oats for $18.50 per share in cash. The firms say the merger will benefit stakeholders, customers and shareholders. FTC filed its suit against the two major natural/organic food industry competitors June 7, fearing the merger would violate federal antitrust laws (1"The Tan Sheet" June 11, 2007, In Brief)...
You may also be interested in...
Feds move to block Wild Oats takeover
Market proximity of two major natural/organic food industry competitors prompts FTC to move against the proposed $670 mil. acquisition of Wild Oats Markets by Whole Foods Market. The June 6 complaint filed in the U.S. District Court for the District of Columbia seeks a temporary restraining order and preliminary injunctive relief blocking the deal pending an administrative trial. FTC is concerned the merger will result in higher prices and reduced quality and services, the commission says. "While we disagree with the FTC's position and believe it is without legal and factual merit, we are confident that, once presented with the facts, the court will agree that this merger is pro-competitive and the FTC's application for injunction is denied," Wild Oats Chairman and CEO Greg Mays states. The companies announced plans Feb. 21 to merge both entities in an agreement under which Whole Food acquires 110 stores via the buyout of Wild Oats (1"The Tan Sheet" Feb. 26, 2007, In Brief)...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.